1. 369 Open-label, single center, phase I trial to investigate the mass balance and absolute bioavailability of the oral c-Met inhibitor tepotinib. (September 2015) Authors: Johne, A.; Scheible, H.; Becker, A.; Van Lier, J.J.; Meyring, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗